Polycystic Ovary Syndrome.
Conditions
Interventions
Intervention 1: Intervention group: 45 ml Concentrated Pomegranate Juice for 8 weeks with 180 cc water, in the afternoon, Takeda factory of East Azarbaijan . Intervention 2: Control group: Does not re
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 18=Age=40 BMI = 25 Being single Not having acute and chronic diseases such as: cardiovascular disease, kidney, liver, diabetes, hypothyroidism, hyperthyroidism, asthma, neoplastic, hyperprolactinemia, malabsorption disorders, hypertension, dyslipidemia, (new or during 6 months). No Depression Not following a specific diet. Not following a specific exercise program. Non-use of drugs such as contraceptive pills (Oral contraceptive pill), hormonal drugs, anti-diabetic drugs, anti-obesity drugs, antioxidant supplements and multivitamin minerals, blood lipid lowering drugs. Not smoking Not allergic to pomegranate and its products. Not consuming pomegranates and pomegranate-containing products at least 2 months before starting the study
Exclusion criteria
Exclusion criteria: Pregnancy Not consuming Concentrated Pomegranate Juice completely Not willing to continue participating in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of malondialdehyde in women with polycystic ovary syndrome. Timepoint: Baseline and 8 weeks after starting the study. Method of measurement: Measurement of serum malondialdehyde by calorimetric method using kiazist kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of total antioxidant capacity in women with polycystic ovary syndrome. Timepoint: Baseline and 8 weeks after starting the study. Method of measurement: Measurement of serum total antioxidant capacity by cupric reducing antioxidant capacity (CUPRAC) method using kiazist kit.;Evaluation of insulin resistance in women with polycystic ovary syndrome. Timepoint: Baseline and 8 weeks after starting the study. Method of measurement: Measurement of Insulin Resistance Using Formula (fasting plasma glucose (mMol/L) × insulin (µIU/mL))/22.5. The levels of serum insulin will be determined using ELISA kit (AccuBind, Monobind Inc., USA) and fasting blood sugar will be measured by enzymatic photometric method using standard kits (Pars Azmun, Tehran, Iran).;Depression score. Timepoint: Baseline and 8 weeks after starting the study. Method of measurement: Depression Anxiety Stress Scale-21 (DASS-21) questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Abedini
Esfahan University of Medical Sciences
Outcome results
None listed